MedPath

COVID-19 Surveillance in Rural Mozambique for Prompt and Effective Response

Completed
Conditions
COVID-19
Registration Number
NCT05228639
Lead Sponsor
Centro de Investigacao em Saude de Manhica
Brief Summary

Extraordinary times require extraordinary measures. The current COVID-19 pandemic is the paradigmatic example of how infectious diseases may menace the world's health and economy, and particularly contribute to enhancing current inequities in health-related to wealth. The main goal of the proposed study is to understand the epidemiology and natural history of COVID-19 in a rural area in Southern Mozambique

Detailed Description

Although Mozambique has so far had few confirmed cases of COVID19, it is unknown if low testing rates and other factors such as the warm climatic conditions may explain the apparently low spread of the virus. The present proposal aims to rapidly gain an understanding of the epidemic curve and natural history of SARS-CoV-2 in a rural area in southern Mozambique through a series of epidemiological indicators obtained at both the health facility and community levels, so as to provide evidence-based recommendations for managing and mitigating the COVID19 epidemic. Age-specific incidence of severe COVID-19 obtained at health facilities during a period of 15 months together with seroprevalence data obtained from the community will be used to determine SARS-CoV-2 reproduction number and effects of interventions through mathematical modeling. Viral, serological, and clinical progression will be assessed in a longitudinal cohort of symptomatic SARS-CoV-2 infected individuals. Community awareness of COVID-19 and of project aims will be fostered through engagement activities among community leaders and members. COVID-19 surveillance capacities in Mozambique will be strengthened by developing SARS-CoV-2 diagnostic approaches (molecular testing and an innovative immunoassay to detect antibodies against the virus), as well as SARS-CoV-2 genome sequencing approaches to identify transmission chains. Finally, the project will pursue the creation of a bank of serum, virus materials, and data which will be open for immediate public health purposes, including the development of point-of-care diagnostic tests. This project will be coordinated by the Manhiça Health Research Centre (Mozambique) in conjunction with the Barcelona Institute for Global Health (Spain), which will lead the transfer of molecular and immunological tools to the Mozambican research center. Imperial College will provide the modeling expertise to derive metrics of transmission, and INS the expertise to conduct quality control of laboratory determinations as well as dissemination and networking with the Ministry of Health in Mozambique. Four WPs will comprise the main research tasks, including COVID-19 surveillance (WP1), Laboratory determinations (WP2), Contact tracing and community awareness (WP3), Modelling (WP4), as well as two cross-cutting WPs related to Capacity-building (WP5) and Scientific coordination, management, networking \& dissemination (WP6). We expect this 21-month project will increase the level of preparedness, alertness, and response in Mozambique

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
6494
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Age-specific positivity rate of SARS-CoV-2 infection15 months

Positivity rate by age-group (0-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, \>=70 years) of SARS-CoV-2 infection among acute respiratory syndrome individuals during 15 months

Age-specific Incidence of SARS-CoV-2 infection15 months

Incidence by age-group (0-9. 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, \>=70 years) of SARS-CoV-2 infection among acute respiratory syndrome individuals during 15 months

Community Age-specific seroprevalencemonth 14

Seroprevalence by age-group (0-19, 20-39, 40-59, \>=60 years) of IgM and IgG against SARS-CoV-2 at baseline andd after 15 months

COVID-19 associated mortality2 years

Factors associated with acute COVID-19, sero-positivity and COVID-19 associated mortality

Secondary Outcome Measures
NameTimeMethod
PCR and antibody-negativizationup to 12 months

Median time (weeks or months) to PCR and antibody-negativization in symptomatic PCR-confirmed acute COVID-19 individuals

Relatedness of SARS-CoV-2 genome15 months

Monophyletic groups of closely related SARS-CoV-2 genome

Trial Locations

Locations (1)

Centro de investigacao em saude de Manhica

🇲🇿

Manhica, Mozambique

© Copyright 2025. All Rights Reserved by MedPath